# Contents

January 15, 2007  
Vol 13, No 2  
(Part 2 of 2)

<table>
<thead>
<tr>
<th>Program Faculty</th>
<th>i</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsorship and CME Credit</td>
<td>ii</td>
</tr>
<tr>
<td>CME Activity Assessment and Evaluation</td>
<td>iii</td>
</tr>
</tbody>
</table>

**Innovations and Challenges in Renal Cell Carcinoma: Summary Statement from the Second Cambridge Conference**  
667s

**Identification of the Genes for Kidney Cancer: Opportunity for Disease-Specific Targeted Therapeutics**  
W. Marston Linehan, Peter A. Pinto, Ramaprasad Srinivasan, Maria Merino, Peter Choyke, Lynda Choyke, Jonathan Coleman, Jorge Toro, Gladys Glenn, Cathy Vocke, Bert Zbar, Laura S. Schmidt, Donald Bottaro, and Len Necker  
671s

**The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma**  
William G. Kaelin, Jr.  
680s

**Genomics of Renal Cell Cancer: The Biology Behind and the Therapy Ahead**  
Jon Jones and Tonia A. Libermann  
685s

**Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?**  
Allan J. Pantuck, Arie S. Beldegrun, and Robert A. Figlin  
693s

**Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Outcome**  
Christopher G. Wood  
697s

**Protein Expression Profiles in Renal Cell Carcinoma: Staging, Prognosis, and Patient Selection for Clinical Trials**  
John S. Lam, Allan J. Pantuck, Arie S. Beldegrun, and Robert A. Figlin  
703s

**Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy**  
R. Houston Thompson, Haidong Dong, and Eugene D. Kwon  
709s

**Update on the Application of Interleukin-2 in the Treatment of Renal Cell Carcinoma**  
David F. McDermott  
716s

**Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma**  
Augusto C. Ochoa, Arnold H. Zea, Claudia Hernandez, and Paulo C. Rodriguez  
721s

**Reversal of Tumor-Mediated Immunosuppression**  
Johannes Vieweg, Zhen Su, Philipp Dahm, and Sergei Kusmartsev  
727s

**Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang**  
733s

**Biologic Aspects and Binding Strategies of Vascular Endothelial Growth Factor in Renal Cell Carcinoma**  
Brian I. Rini and W. Kimryn Rathmell  
741s

**Sorafenib in Renal Cell Carcinoma**  
Keith T. Flaherty  
747s

**Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell Carcinoma**  
Daniel J. George  
753s
The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer
Daniel Cho, Sabina Signoretti, Meredith Regan, James W. Mier, and Michael B. Atkins

Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell Cancer
Jeffrey A. Sosman, Igor Puzanov, and Michael B. Atkins

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma
Mark A. Rosen and Mitchell D. Schnall

Biomarkers for Monitoring Antiangiogenic Therapy
Rupal S. Bhatt, Pankaj Seth, and Vikas P. Sukhatme